Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy Academic Article uri icon

Overview

MeSH Major

  • Adjuvants, Immunologic
  • Antibodies, Monoclonal
  • Melanoma
  • Skin Neoplasms

abstract

  • As adjuvant therapy for high-risk stage III melanoma, ipilimumab at a dose of 10 mg per kilogram resulted in significantly higher rates of recurrence-free survival, overall survival, and distant metastasis-free survival than placebo. There were more immune-related adverse events with ipilimumab than with placebo. (Funded by Bristol-Myers Squibb; ClinicalTrials.gov number, NCT00636168 , and EudraCT number, 2007-001974-10 .).

publication date

  • November 10, 2016

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC5648545

Digital Object Identifier (DOI)

  • 10.1056/NEJMoa1611299

PubMed ID

  • 27717298

Additional Document Info

start page

  • 1845

end page

  • 1855

volume

  • 375

number

  • 19